Healthcare and Cancer Treatment Costs of Breast Screening Outcomes among Higher than Average Risk Women

Author:

Mittmann Nicole12,Blackmore Kristina M.3ORCID,Seung Soo Jin4,Diong Christina5,Done Susan J.6,Chiarelli Anna M.37

Affiliation:

1. Department of Pharmacology & Toxicology, University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada

2. Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON M4G 3M5, Canada

3. Ontario Health, 525 University Avenue, 5th Floor, Toronto, ON M5G 2L3, Canada

4. HOPE Research Centre, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada

5. ICES Central, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada

6. Laboratory Medicine Program, University Health Network, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada

7. Dalla Lana School of Public Health, University of Toronto, 155 College Street, Toronto, ON M5T 3M7, Canada

Abstract

Concurrent cohorts of 644,932 women aged 50–74 screened annually due to family history, dense breasts or biennially in the Ontario Breast Screening Program (OBSP) from 2011–2014 were linked to provincial administrative datasets to determine health system resource utilization and costs. Age-adjusted mean and median total healthcare costs (2018 CAD) and incremental cost differences were calculated by screening outcome and compared by recommendation using regression models. Healthcare costs were compared overall and 1 year after a false positive (n = 46,081) screening mammogram and 2 years after a breast cancer diagnosis (n = 6011). Mean overall healthcare costs by age were highest for those 60–74, particularly with annual screening for family/personal history (CAD 5425; 95% CI: 5308 to 5557) compared to biennial. Although the mean incremental cost difference was higher (23.4%) by CAD 10,235 (95% CI: 6141 to 14,329) per breast cancer for women screened annually for density ≥ 75% compared to biennially, the cost difference was 12.0% lower (−CAD 461; 95% CI: −777 to −114) per false positive result. In contrast, for women screened annually for family/personal history, the mean cost difference per false positive was 19.7% higher than for biennially (CAD 758; 95% CI: 404 to 1118); however, the cost difference per breast cancer was only slightly higher (2.5%) by CAD 1093 (95% CI: −1337 to CAD 3760). Understanding that associated costs of annual compared to biennial screening may balance out by age and outcome can assist decision-making regarding the use of limited healthcare resources.

Funder

Canadian Cancer Society

ICES

Publisher

MDPI AG

Reference35 articles.

1. Canadian Cancer Statistics (2021). Canadian Cancer Statistics Advisory Committee in Collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada, Canadian Cancer Society. Available online: cancer.ca/canadian-cancer-statistics-2021-en.

2. (2018). Canadian Task Force on Preventive Health Care. Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer. CMAJ, 190, E1441–E1451.

3. Biologic characteristics of interval and screen-detected breast cancers;Gilliland;J. Natl. Cancer Inst.,2000

4. Favourable prognostic factors of subsequent screen-detected breast cancers among women aged 50–69;Chiarelli;Eur. J. Cancer Prev.,2012

5. A study of interval breast cancer within the NHS breast screening programme;Cowan;J. Clin. Pathol.,2000

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3